Yıl: 2015 Cilt: 31 Sayı: 2 Sayfa Aralığı: 61 - 64 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi

Öz:
Amaç: Gastrointestinal stromal tümörlerin lokal etkileriyle immünsupresyonda rol oynadığı düşünülmektedir. İnflamasyonla ilişkili bazı kanserlerde tedavi öncesi nötrofil lenfosit oranındaki artış kötü prognozun göstergesi olarak kabul edilmektedir. Çalışmamızın amacı gastrointestinal stromal tümör hastalarında kan nötrofil lenfosit oranı ile hastalığın prognozunu değerlendirmektir. Gereç ve Yöntemler: Kliniğimizde primer gastrointestinal stromal tümör nedeniyle cerrahi uygulanan 78 hastanın verileri retrospektif olarak değerlendirildi. Hastaların operasyon öncesi periferik kandan bakılan nötrofil lenfosit oranları belirlendi. Nötrofil lenfosit oranı ile tümör riski ve prognoz arasındaki ilişki karşılaştırıldı. Verilerin değerlendirilmesinde Pearson korelasyon analizi ve ANOVA Welch testi kullanıldı. Bulgular: Preoperatif nötrofil lenfosit oranındaki artış patolojik olarak yüksek riskli gastrointestinal stromal tümör gruplarında anlamlıydı (p<0,05). Preoperatif nötrofil lenfosit oranı yüksek olan hastaların sağkalımları düşüktü (r=- 0,32, p=0,009). Ayrıca nötrofil lenfosit oranı artışı ile tümör mitotik aktivitesi artışı benzerdi (r=-0,364, p=0,025). Sonuç: Gastrointestinal stromal tümörlerde preoperatif nötrofil lenfosit oranı yüksek riskli tümörlerin belirlenmesinde ve kötü prognozun göstergesi olarak kullanılabilecek bir parametredir.
Anahtar Kelime:

Konular: Onkoloji

Relationship of preoperative neutrophil lymphocyte ratio with prognosis in gastrointestinal stromal tumors

Öz:
Objective: Gastrointestinal stromal tumors are believed to play a role in immunosuppression with their local effect. In some cancers with associated inflammation, an increased pretreatment neutrophil lymphocyte ratio is considered as an indicator of poor prognosis. The aim of our study was to assess the relationship of increased blood neutrophil lymphocyte ratio with disease prognosis in patients with gastrointestinal stromal tumors. Material and Methods: The data of 78 patients who underwent surgery with the diagnosis of primary gastrointestinal stromal tumor in our clinic were evaluated retrospectively. The preoperative neutrophil lymphocyte ratio in the peripheral blood was determined. The neutrophil lymphocyte ratio and its relationship with tumor risk and prognosis were compared. The data were evaluated by Pearson's correlation analysis and the Welch ANOVA test. Results: The preoperative neutrophil lymphocyte ratio was significantly increased in the high-risk groups (p<0.05). An increased preoperative neutrophil lymphocyte ratio was associated with shorter survival (r=-0.32, p=0.009). In addition, an increase in the neutrophil lymphocyte ratio was associated with an increase in the mitotic activity of the tumor (r=-0.364, p=0.025). Conclusion: The preoperative neutrophil lymphocyte ratio in gastrointestinal stromal tumors can be used as an indicator of high-risk tumors and poor prognosis.
Anahtar Kelime:

Konular: Onkoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointes- tinal stromal tumors. Science 1998; 279: 577-580. [CrossRef]
  • Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Jo- seph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708-710. [CrossRef]
  • Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Terva- hartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tu- mor. N Engl J Med 2001; 344: 1052-1056. [CrossRef]
  • Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, pri- mary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104. [CrossRef]
  • Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465. [CrossRef]
  • Blanke CD, Rankin C, Demetri GD, Ryan CW, Von Mehren M, Benja- min RS, et al. Phase III randomized, intergroup trial assessing imati- nib mesylate at two dose levels in patients with unresectable or me- tastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. [CrossRef]
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. [CrossRef]
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generati- on. Cell 2011; 144: 646-674. [CrossRef]
  • Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
  • Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fu- kushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007; 73: 215-220. [CrossRef]
  • Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre- treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Im- munol Immunother 2009; 58: 15-23. [CrossRef]
  • Perez DR, Baser RE, Cavnar MJ, Balachandran VP, Antonescu CR, Tap WD, et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastro- intestinal stromal tumor. Ann Surg Oncol 2013; 20: 593-599. [CrossRef]
  • Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advan- ced gastrointestinal stromal tumors are predicted by different prog- nostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804. [CrossRef]
  • Gastrointestinal Stromal Tumor Meta-Analysis Group (Meta-GIST). Comparison of two doses of imatinib for the treatment of unresec- table or metastatic gastrointestinal stromal tumors: a meta-analy- sis of 1,640 patients. J Clin Oncol 2010; 28: 1247-1253. [CrossRef]
  • Ji F, Wang ZW, Wang LJ, Ning JW, Xu GQ. Clinicopathological characteristics of gastrointestinal mesenchymal tumors and di- agnostic value of endoscopic ultrasonography. J Gastroenterol Hepatol 2008; 23: 318-324. [CrossRef]
  • Verweij PJ, Casali PG, Zalcberg PJ, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high- dose Imatinib: randomized trial. Lancet 2004; 364: 1127-1134. [CrossRef]
  • Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and drug administration drug approval summary: Sunitinib ma- late for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12: 107-113. [CrossRef]
  • Azuma T, Matayoshi Y, Odani K, Sato Y, Sato Y, Nagase Y, et al. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 2013; 11: 337-341. [CrossRef]
  • Tanimine N, Tanabe K, Suzuki T, Tokumoto N, Ohdan H. Prog- nostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis. World J Surg Oncol 2012; 10: 43. [CrossRef]
  • Öztürk S, Erdem A, Özlü MF, Ayhan S, Erdem K, Özyaşar M, et al. Assess- ment of the neutrophil to lymphocyte ratio in young patients with acute coronary syndromes. Arch Turk Soc Cardiol 2013; 41: 284-289. [CrossRef]
  • Kapçı M, Türkdoğan KA, Duman A, Avcil M, Gülen B, Uğurlu Y, et al. Biomarkers in the diagnosis of acute appendicitis. J Clin Exp Invest 2014; 5: 250-255. [CrossRef]
  • Kahramanca S, Ozgehan G, Seker D, Gökce EI, Seker G, Tunç G, et al. Neutrophil-to-lymphocyte ratio as a predictor of acute appen- dicitis. Ulus Travma Acil Cerrahi Derg 2014; 20: 19-22. [CrossRef]
  • Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neut- rophils responsive to endogenous IFN-beta regulate tumor angi- ogenesis and growth in a mouse tumor model. J Clin Invest 2010; 120: 1151-1164. [CrossRef]
  • Müller I, Munder M, Kropf P, Hänsch GM. Polymorphonuclear ne- utrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol 2009; 30: 522-530. [CrossRef]
  • Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 218-230. [CrossRef]
  • Wang GY, Yang Y, Li H, Zhang J, Jiang N, Li MR, et al. A scoring mo- del based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplan- tation. PLoS One 2011; 6: e25295. [CrossRef]
  • Halazun KJ, Hardy KJ, Rana AA, Woodland DC, Luyten EJ, Maha- dev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151. [CrossRef]
  • Bertuzzo VR, Cescon M, Ravaioli M, Grazi GL, Ercolani G, Del Gaudio M, et al. Analysis of factors affecting recurrence of hepatocellular car- cinoma after liver transplantation with a special focus on inflamma- tion markers. Transplantation 2011; 91: 1279-1285. [CrossRef]
  • Sato H, Tsubosa Y, Kawano T. Correlation between the prethera- peutic neutrophil to lymphocyte ratio and the pathologic res- ponse to neoadjuvant chemotherapy in patients with advanced esophageal cancer. World J Surg 2012; 36: 617-622. [CrossRef]
  • Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med 2011; 2: 879-885. [CrossRef]
  • Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011; 18: 3362-3369. [CrossRef]
APA KARGIN S, CAKIR M, Gündeş E, Yavuz Y, ESEN H, İYİSOY M, KÖKBUDAK N, KÜÇÜKKARTALLAR T (2015). Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. , 61 - 64.
Chicago KARGIN SÜLEYMAN,CAKIR Murat,Gündeş Ebubekir,Yavuz Yusuf,ESEN HACI HASAN,İYİSOY M Sinan,KÖKBUDAK Naile,KÜÇÜKKARTALLAR Tevfik Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. (2015): 61 - 64.
MLA KARGIN SÜLEYMAN,CAKIR Murat,Gündeş Ebubekir,Yavuz Yusuf,ESEN HACI HASAN,İYİSOY M Sinan,KÖKBUDAK Naile,KÜÇÜKKARTALLAR Tevfik Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. , 2015, ss.61 - 64.
AMA KARGIN S,CAKIR M,Gündeş E,Yavuz Y,ESEN H,İYİSOY M,KÖKBUDAK N,KÜÇÜKKARTALLAR T Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. . 2015; 61 - 64.
Vancouver KARGIN S,CAKIR M,Gündeş E,Yavuz Y,ESEN H,İYİSOY M,KÖKBUDAK N,KÜÇÜKKARTALLAR T Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. . 2015; 61 - 64.
IEEE KARGIN S,CAKIR M,Gündeş E,Yavuz Y,ESEN H,İYİSOY M,KÖKBUDAK N,KÜÇÜKKARTALLAR T "Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi." , ss.61 - 64, 2015.
ISNAD KARGIN, SÜLEYMAN vd. "Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi". (2015), 61-64.
APA KARGIN S, CAKIR M, Gündeş E, Yavuz Y, ESEN H, İYİSOY M, KÖKBUDAK N, KÜÇÜKKARTALLAR T (2015). Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. Ulusal Cerrahi Dergisi, 31(2), 61 - 64.
Chicago KARGIN SÜLEYMAN,CAKIR Murat,Gündeş Ebubekir,Yavuz Yusuf,ESEN HACI HASAN,İYİSOY M Sinan,KÖKBUDAK Naile,KÜÇÜKKARTALLAR Tevfik Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. Ulusal Cerrahi Dergisi 31, no.2 (2015): 61 - 64.
MLA KARGIN SÜLEYMAN,CAKIR Murat,Gündeş Ebubekir,Yavuz Yusuf,ESEN HACI HASAN,İYİSOY M Sinan,KÖKBUDAK Naile,KÜÇÜKKARTALLAR Tevfik Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. Ulusal Cerrahi Dergisi, vol.31, no.2, 2015, ss.61 - 64.
AMA KARGIN S,CAKIR M,Gündeş E,Yavuz Y,ESEN H,İYİSOY M,KÖKBUDAK N,KÜÇÜKKARTALLAR T Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. Ulusal Cerrahi Dergisi. 2015; 31(2): 61 - 64.
Vancouver KARGIN S,CAKIR M,Gündeş E,Yavuz Y,ESEN H,İYİSOY M,KÖKBUDAK N,KÜÇÜKKARTALLAR T Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi. Ulusal Cerrahi Dergisi. 2015; 31(2): 61 - 64.
IEEE KARGIN S,CAKIR M,Gündeş E,Yavuz Y,ESEN H,İYİSOY M,KÖKBUDAK N,KÜÇÜKKARTALLAR T "Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi." Ulusal Cerrahi Dergisi, 31, ss.61 - 64, 2015.
ISNAD KARGIN, SÜLEYMAN vd. "Gastrointestinal stromal tümörlerde prognozun belirlenmesinde preoperatif nötrofil lenfosit oranının etkisi". Ulusal Cerrahi Dergisi 31/2 (2015), 61-64.